Irish footballer diagnosed with MALT lymphoma
Professional footballer Stephen McPhail, a 29 year old Irish star midfielder for Cardiff City FC and the Republic of Ireland, has Stage I MALT lymphoma and will undergo three weeks of treatment, according to the BBC.
In an official statement, Cardiff City says they expect McPhail to return to the team by January of 2010.
Mucosa-associated lymphoid tissue (MALT) lymphoma is a very rare subtype of extranodal marginal zone lymphoma. About 3,700 people are diagnosed with this indolent lymphoma each year, the majority of them aged 60 or older. Early-stage MALT lymphomas can often be treated with antibiotics, although sometimes chemotherapy and/or radiation is required.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
